<ul data-eligibleForWebStory="false"><li>Isomorphic Labs, using AI in drug development, aims to accelerate timelines and improve outcomes, potentially reducing costs and speeding up treatment delivery.</li><li>They will test compounds developed through AI, including AlphaFold 3, capable of predicting protein structures and interactions with DNA and drug molecules.</li><li>Isomorphic Labs, founded in 2021, secured over $600 million in funding and partnered with big pharma to advance its AI-driven drug pipeline, focusing on oncology and immunology.</li><li>While the exact details of the upcoming trials are undisclosed, success could validate AI in drug discovery, revolutionizing the industry in treating complex diseases like cancer.</li></ul>

AI-Designed Cancer Drugs Near Human Trials, Marking a Major Milestone in Drug Discovery | VBM

Discover more